In the last trading session, 6.77 million BridgeBio Pharma Inc (NASDAQ:BBIO) shares changed hands as the company’s beta touched 1.06. With the company’s per share price at $34.35 changed hands at -$1.9 or -5.24% during last session, the market valuation stood at $6.53B. BBIO’s last price was a discount, traded about -14.91% off its 52-week high of $39.47. The share price had its 52-week low at $21.62, which suggests the last value was 37.06% up since then.
Analysts gave the BridgeBio Pharma Inc (BBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.35. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BBIO as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. BridgeBio Pharma Inc’s EPS for the current quarter is expected to be -0.86.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
Instantly BBIO was in red as seen at the end of in last trading. With action -3.21%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 25.18%, with the 5-day performance at -3.21% in the red. However, in the 30-day time frame, BridgeBio Pharma Inc (NASDAQ:BBIO) is -8.62% down.
The consensus price target for the stock as assigned by Wall Street analysts is 46, meaning bulls need an upside of 25.33% from its current market value. According to analyst projections, BBIO’s forecast low is 45 with 53 as the target high. To hit the forecast high, the stock’s price needs a -54.29% plunge from its current level, while the stock would need to soar -31.0% for it to hit the projected low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
Year-over-year growth is forecast to reach -6.25% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 56.25M. 10 analysts are of the opinion that BridgeBio Pharma Inc’s revenue for the current quarter will be 43.31M. The company’s revenue for the corresponding quarters a year ago was 211.12M and 2.17M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -73.36%. The estimates for the next quarter sales put growth at 1,897.82%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -3.04%. The 2025 estimates are for BridgeBio Pharma Inc earnings to decrease by -27.73%, but the outlook for the next 5-year period is at 51.30% per year.
BBIO Dividends
BridgeBio Pharma Inc is expected to release its next quarterly earnings report in March.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 13.3917% or 25.12 million shares worth $636.31 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 4.53 shares estimated at $155.67 million under it, the former controlled 2.38% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.07% of the shares, roughly 3.93 shares worth around $135.06 million.
